References
- Global Initiative for Chronic Obstructive Lung DiseasesGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary DiseaseVancouver, WAGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2014
- World Health ReportGenevaWorld Health Organization2000 Available from: http://www.who.int/whr/2000/en/statistics.htmAccessed July 1, 2016
- MathersCDLoncarDProjections of global mortality and burden of diseases from 2002 to 2030PLoS Med2006311e44217132052
- SuissaSDell’AnielloSErnstPLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax2012671195796322684094
- de MeloMNErnstPSuissaSInhaled corticosteroids and the risk of a first exacerbation in COPD patientsEur Respir J200423569269715176681
- BourbeauJErnstPCockcoftDSuissaSInhaled corticosteroids and hospitalisation due to exacerbation of COPDEur Respir J200322228628912952262
- SuissaSNumber needed to treat in COPD: exacerbations versus pneumoniasThorax201368654054323125170
- de MeloMNErnstPSuissaSRates and patterns of chronic obstructive pulmonary disease exacerbationsCan Respir J200411855956415611805
- CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
- CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
- CalverleyPMBoonsawatWCsekeZMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
- SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
- JansonCLarssonKLisspersKHPneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)BMJ2013346f330623719639
- WangCYLaiCCYangWCThe association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) studyInt J Chron Obstruct Pulmon Dis2016112775278327877031
- LarssonKJansonCLisspersKCombination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS studyJ Intern Med2013273658459423495860
- HastieTTibshiraniRExploring the nature of covariate effects in the proportional hazards modelBiometrics1990464100510161964808
- BlaisLForgetARamachandranSRelative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherenceClin Ther20103271320132820678680
- TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
- RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
- ThorssonLEdsbäckerSKällénAPharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via TurbuhalerBr J Clin Pharmacol200152552953811736861
- DalbyCPolanowskiTLarssonTThe bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trialRespir Res20091010419878590
- BrattsandRMiller-LarssonAThe role of intracellular esterification in budesonide once-daily dosing and airway selectivityClin Ther200325Suppl CC28C4114642802
- EkALarssonKSiljerudSFluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophagesAllergy199954769169910442524